Cargando…

Role of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer in the COVID-19 Pandemic

Introduction Cancer patients are among the groups at high risk in the COVID-19 pandemic. Here, we aimed to determine the effectiveness of neoadjuvant chemotherapy (NACT) during the pandemic period and examine the prognostic factors in patients with non-small cell lung cancer (NSCLC). Method Patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karaman, Elanur, Ulas, Arife, Onder, Arif Hakan, Deligonul, Adem, Orhan, Sibel O, Pekcolaklar, Atilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520232/ https://www.ncbi.nlm.nih.gov/pubmed/36187171 http://dx.doi.org/10.7759/cureus.29720

Ejemplares similares

Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy
por: Şahin, Ahmet Bilgehan, et al.
Publicado: (2021)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
por: Dai, Fuqiang, et al.
Publicado: (2022)

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study
por: Fei, Kailun, et al.
Publicado: (2023)

Efficacy of chemotherapeutics on classic and non-classic Kaposi sarcoma: a single-center retrospective real-world study
por: Orhan, Sibel Oyucu, et al.
Publicado: (2021)

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
por: Shi, Liang, et al.
Publicado: (2022)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
por: Alì, Greta, et al.
Publicado: (2023)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Successful Neoadjuvant Chemotherapy for Small-Cell Neuroendocrine Carcinoma of the Pancreas: A Case Report
por: Li, Keyu, et al.
Publicado: (2021)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

Is There Any Relationship Between the Number of COVID-19 Tests by Country with the Income Inequality of Countries? A Comparison with Income Inequality Metrics
por: Çıtak, Necati, et al.
Publicado: (2022)

Inflammatory prognostic index predicts new-onset atrial fibrillation and mortality after on-pump coronary artery bypass grafting
por: Badem, Serdar, et al.
Publicado: (2023)

Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer
por: Lewis, Jennifer, et al.
Publicado: (2018)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer
por: Sun, Juan, et al.
Publicado: (2021)

Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report
por: Fan, YH, et al.
Publicado: (2022)

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
por: Shi, Xiaoshun, et al.
Publicado: (2021)

Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
por: Patel, Manali I., et al.
Publicado: (2011)

Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
por: Ulas, Ezgi B., et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
por: Bai, Rilan, et al.
Publicado: (2020)

Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer
por: Chen, Jiawei, et al.
Publicado: (2022)

Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
por: Zeng, Jun, et al.
Publicado: (2023)

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer
por: Qi, Yuwen, et al.
Publicado: (2023)

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022)

Body composition change during neoadjuvant chemotherapy for breast cancer
por: Jang, Min Kyeong, et al.
Publicado: (2022)

Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Lu, Ying, et al.
Publicado: (2022)

The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors
por: Wang, Yujie, et al.
Publicado: (2022)

CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy
por: Lin, Qian, et al.
Publicado: (2022)

Erratum: Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Publicado: (2023)

The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis
por: Bozcuk, Hakan, et al.
Publicado: (2012)

The safety of neoadjuvant chemotherapy combined with non-tube nofasting fast-track surgery for esophageal carcinoma
por: Zheng, Yan, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis
por: Zhang, Baihua, et al.
Publicado: (2023)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes
por: Adham, Sirin A., et al.
Publicado: (2022)

Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress
por: Chen, Yushi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ular718cct23sbkbp6ct06sgjl